Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Enzalutamide (Xtandi) for Metastatic Castration Sensitive Prostate Cancer
(Open for Input on Submission until March 9, 2020)

Niraparib (Zejula) for Ovarian Cancer
(Open for Input on Submission until February 24, 2020)

Atezolizumab (Tecentriq) for Small Cell Lung Cancer
(Notification to Implement Issued as of February 14, 2020)

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer
(Notification to Implement Issued as of February 14, 2020)

Find a Drug Review